Pharmafile Logo

Asterias Biotherapeutics

- PMLiVE

Roche’s Alecensa backed by China’s National Drug Administration

Approved to treat ALK-positive lung cancer

- PMLiVE

Cancer Research UK to test Asterias’ lung cancer vaccine

The vaccine could treat NSCLC patients who are at risk of relapse

- PMLiVE

Keytruda cleared for frontline lung cancer in England – but only after another pricing deal

Keytruda first drug to exit Cancer Drugs Fund and go through Budget Impact Test

- PMLiVE

Safety scuppers combo trials with J&J/Genmab’s Darzalex

Studies revealed a “numerical increase” in patient deaths when Darzalex was combined with Roche’s Tecentriq

- PMLiVE

Immuno-oncology at ASCO: survival data, combinations and new indications

The abstracts reveal heaps of strong contenders in the NSCLC category

Roche Basel Switzerland

Roche eyes September FDA verdict for triple NSCLC therapy

Roche hot on the heels of Merck in first-line non-small cell lung cancer market

Sanofi reception

Sanofi’s latecomer PD-1 gets date for FDA verdict

While Keytruda extends its lead, Sanofi makes a late bid to enter PD-1 space

AstraZeneca AZ

AZ’s immuno-oncology combo fails another lung cancer trial

Latest failure casts doubt on company’s CTLA4 drug

- PMLiVE

Merck’s Keytruda meets survival challenge in NSCLC

Data showed that almost 70% of patients on the combo were still alive after 12 months

- PMLiVE

AZ makes case for first-line Tagrisso therapy in lung cancer

Data shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

- PMLiVE

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Both EU and US regulatory advisors are currently assessing the drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links